Close
American Drug Delivery & Formulation Summit
Xylem

Expansion of Analytical Laboratories at Tredegar Center of Excellence for Contained Manufacturing

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access the Media Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Related stories

Shilpa Biologicals Launches Integrated ADC Production Site in India

Shilpa Biologicals Ltd, a subsidiary of Shilpa Medicare Ltd,...

CPHI Milan 2026 Unveils Dedicated Innovation Hubs for Pharma Manufacturing

CPHI Milan 2026, recognized as a premier global gathering...

Sanofi Partners with Pangaea for AI-Driven AATD Detection

Pangaea Data (Pangaea), a provider of a guideline-configured AI...
- Advertisement -

The Tredegar facility is our development and manufacturing Center of Excellence with specialist expertise in the processing of highly potent molecules. The site has undergone significant investments over recent years; this latest project ensures analytical capacity and capability to service increasing customer demand.

The investment will see the laboratory increase its analyst headcount by approximately 60 percent and increase its High-Performance Liquid Chromatography (HPLC) capacity in excess of 20 percent, in addition to tripling its capacity for sample receipt. The layout design of the facility incorporates state-of-the-art Lean philosophies and optimized safety, combined with leading ergonomic principles, to deliver enhanced throughput and additional efficiency improvements.

Since launching the contained manufacturing facility, utilizing the latest in containment technology at Tredegar; the site has seen significant growth in its global customer base. This latest project will ensure that we are able to service both existing and potential new clients, as well as offering a project initiation in terms of analytical transfer within 4-6 weeks.

The site offers a true Center of Excellence for the development and manufacturing of pharmaceutical products in a variety of dosage forms and has over 30 years of experience in the specialist handling of potent molecules. Investment in state-of-the-art contained equipment, combined with the creation of a โ€˜Potent Passportโ€™ philosophy to identify the specific handling requirements for every Highly Potent Active Pharmaceutical Ingredient (HPAPI) project, defines PCI as a market leader within this space. Contained technology includes Xcelodoseยฎ micro-dosing for early stage development drug-in-capsule (DIC), fluid bed granulation and roller compaction for products sensitive to heat and moisture.
Commenting on the expansion, PCI Senior Vice President, International, Richard Yarwood said: โ€œExpansion of our laboratory services is an important program for the Tredegar site. Speed to market is of critical importance to our clients. We pride ourselves on continually improving our service for both existing and potential new clients and our analytical service is integral from the early stages of analytical development through to commercial launch and the associated annual stability testing.โ€
He continued โ€œAmong our many key strengths is our ability to on-board projects faster than our competitors. This additional footprint will ensure we are able to continue to offer this speed of project initiation addressing customer need.โ€œ

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast โ€“ stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Latest stories

Related stories

Shilpa Biologicals Launches Integrated ADC Production Site in India

Shilpa Biologicals Ltd, a subsidiary of Shilpa Medicare Ltd,...

CPHI Milan 2026 Unveils Dedicated Innovation Hubs for Pharma Manufacturing

CPHI Milan 2026, recognized as a premier global gathering...

Sanofi Partners with Pangaea for AI-Driven AATD Detection

Pangaea Data (Pangaea), a provider of a guideline-configured AI...

Shilpa Biologicals Launches PartnerPower Platform for CDMOs

Shilpa Biologicals Pvt. Ltd. (SBPL) has introduced PartnerPower Platform,...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access theMedia Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Translate ยป